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SUMMARY
Abnormal stem cell function makes a known contri-
bution to many malignant tumors, but the role of
stem cells in benign tumors is not well understood.
Here, we show that ossifying fibroma (OF) contains
a stem cell population that resembles mesenchymal
stem cells (OFMSCs) and is capable of generating
OF-like tumor xenografts. Mechanistically, OFMSCs
show enhanced TGF-b signaling that induces aber-
rant proliferation and deficient osteogenesis via
Notch and BMP signaling pathways, respectively.
The elevated TGF-b activity is tightly regulated by
JHDM1D-mediated epigenetic regulation of throm-
bospondin-1 (TSP1), forming a JHDM1D/TSP1/
TGF-b/SMAD3 autocrine loop. Inhibition of TGF-b
signaling in OFMSCs can rescue their abnormal
osteogenic differentiation and elevated proliferation
rate. Furthermore, chronic activation of TGF-b can
convert normal MSCs into OF-like MSCs via es-
tablishment of this JHDM1D/TSP1/TGF-b/SMAD3
autocrine loop. These results reveal that epigenetic
regulation of TGF-b signaling in MSCs governs the
benign tumor phenotype in OF and highlight TGF-b
signaling as a candidate therapeutic target.
INTRODUCTION
Ossifying fibroma (OF) is a common benign fibro-osseous
neoplasm of orofacial bones, which causes progressive enlarge-
ment of the affected jaw along with a deficiency in bone forma-
tion (Gondivkar et al., 2011). Currently, complete surgical
removal of the affected bone is widely recommended in the
management of OF. However, patients often suffer from difficult
reconstruction with postsurgical disfigurement, high and un-
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(MacDonald-Jankowski, 2009). Therefore, more appropriate
treatments for OF are needed.
A plethora of tumor stem cells have been identified in a vast
array of tumors, especially in malignancies (Xu et al., 2009;
Zhang et al., 2009). This population of cancer stem cells, usually
accounting for a small percentage of bulk tumor cells, is re-
garded as a driver of tumor growth, progress, metastasis, and
recurrence, implying that effective therapy should be targeted
at this population of cells (Visvader and Lindeman, 2012). In addi-
tion, peripheral nerve progenitors have been shown to be asso-
ciated with benign neurofibroma tumorigenesis (Williams et al.,
2008). However, the detailed molecular mechanisms and regula-
tory networks that determine stem cell function in most benign
tumors, including OF, are largely unknown.
Mesenchymal stem cells (MSCs) are stromal progenitor cells
capable of self-renewal, multilineage differentiation, and immu-
nomodulation (Pittenger et al., 1999; Uccelli et al., 2007).
MSCs have therefore been used in clinical settings for tissue
regeneration and immune therapies (Caplan, 2007; Tang et al.,
2009). Additionally, multiple lines of evidence indicate that
stem cell properties of MSCs may affect cancer and benign
tumor behavior (Mani et al., 2008). However, it remains largely
unknown how MSCs participate in benign tumor development.
Among the different signaling pathways involved inMSCprolifer-
ation and differentiation, TGF-b signaling is of interest because it
has been reported to be associated with both stem cell function
and tumor development (Massague´, 2008; Roelen and Dijke,
2003). TGF-b signaling enhances MSC proliferation via nuclear
translocation of b-catenin in a SMAD3-dependent manner (Jian
et al., 2006) and inhibits MSC differentiation via repression of
RUNX2 function (Kang et al., 2005). It remains unknown whether
TGF-b signaling is involved in the development of mesenchymal-
cell-associated benign tumors. In this study, we reveal that OF
tumors contain mesenchymal stem cells (OFMSCs) capable of
recapitulating the parental tumor phenotype when implanted
in vivo. TGF-b signaling is highly activated in OFMSCs by
the JHDM1D-mediated TSP1/TGF-b/SMAD3 autocrine loop,
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Benign Tumor Mesenchymal Stem Cells in Ossifying Fibromacontributing to the OF phenotype characterized by suppressed
bone formation and aggressive stromal tissue growth.
RESULTS
Benign Ossifying Fibroma Contains Mesenchymal Stem
Cells
In order to determinewhether OF tumors contain progenitor cells
that are capable of regenerating OF-like lesions, we established
primary MSC culture from four surgically resected OF samples,
which were clinically diagnosed and histologically confirmed as
OF benign neoplasm. These OFMSCs showed morphology
similar to normal jawbone-derived MSCs (JMSCs) and ex-
pressed the distinct MSC markers STRO-1, CD90, CD146, and
CD105, but not the hematopoietic lineage markers CD34 and
CD45 (Figure S1A, available online). A small subset of OFMSCs
also expressed PDGFR-a, which is marker of multipotent MSCs
known from murine bone marrow (Figure S1A) (Morikawa et al.,
2009). Compared to the control JMSCs, OFMSCs are capable
of generating more single-colony clusters and have elevated
rates of proliferation and population doubling (Figures 1A and
S1C); immunohistochemical staining further confirmed that OF
tumor samples contain more abundant PCNA-labeled prolifera-
tive cells than do normal jawbones (Figure 1B).
To evaluate their differentiation potential, we demonstrated
that OFMSCs exhibited decreased osteogenic differentiation
capacity as compared to control JMSCs, shown by diminished
mineralized nodule formation and reduced expression of the
osteogenic markers runt-related transcription factor 2 (Runx2)
and osteocalcin (Ocn) (Figures 1C, S1B, S1D, and S1E).
OFMSCs also exhibited decreased adipogenic differentiation,
as indicated by a reduced number of Oil Red O-positive adi-
pocytes and downregulation of adipogenic markers peroxi-
some proliferator-activated receptor gamma 2 (Pparg2) and
lipoprotein lipase (Lpl) (Figures 1D, S1B, S1D, and S1E). In
addition, OFMSCs displayed a chondrogenic differentiation
deficiency, as shown by a reduced number of toluidine-blue-
positive chondrocytes and suppressed expression of Collagen
II and Sox9 (Figures 1E, S1B, S1D, and S1E). When OFMSCs
were subcutaneously implanted into immunocompromised
mice with hydroxyapatite-tricalcium phosphate (HA/TCP) as a
carrier, OFMSCs regained histo-pathological features of OF
lesions, characterized by impaired bone formation and
increased growth of stromal tissue, whereas control JMSC
implants did not (Figure 1F).
To demonstrate the specific role of OFMSCs in OF formation,
we isolated cells on the basis of two widely used markers for
human mesenchymal stem cells, STRO-1 and CD146 (Sacchetti
et al., 2007). When implanted into immunocompromised mice
subcutaneously, only STRO-1+/CD146+ OFMSCs were capable
of generating OF-like lesions with scattered bone nodules and
highly proliferative stromal cells, as indicated by PCNA staining;
implantation of STRO-1/CD146 cells failed to induce OF-like
lesions or mineralized tissue (Figure S1F).
Since MSCs have been recognized as a heterogeneous cell
population containing different subpopulations of stem cells
with variable proliferation and differentiation capacities, we
further characterized single-colony-derived OFMSCs. These
OFMSC colonies exhibited a wide range of enhanced population
R
ET
A578 Cell Stem Cell 13, 577–589, November 7, 2013 ª2013 Elsevier Indoubling and proliferation rates, as well as suppressed in vitro
osteogenic activity, similar to colonies derived from normal
MSCs (Figure S1G). Importantly, these single-colony-derived
OFMSCs are also capable of regenerating OF-like lesions, as
observed in OFMSC implantation (Figure S1H). These results
indicate that OFMSCs exhibit a multilineage differentiation defi-
ciency, a feature exhibited by tumor progenitor cells.
To characterize the in vivo self-renewal property of OFMSCs,
we performed serial implantation of single-colony-derived
OFMSCs (Figure 1G). We found that single-colony-derived
OFMSCs expanded in culture were able to generate prominent
stromal tissue when subcutaneously implanted into immuno-
compromised mice with the use of gelfoam as a carrier vehicle
(1 implant), whereas JMSC implants were not (Figure 1H).
Next, we isolated and expanded OFMSCs from the 1 implant
and subcutaneously implanted them into immunocompromised
mice. The secondary OFMSCs were also capable of regenerat-
ing stromal tissue (2 implant). OFMSCs isolated from both 1
and 2 implants were capable of forming single-colony clusters
(colony-forming unit fibroblasts, CFU-f) (Figure 1H), maintaining
osteogenic and adipogenic differentiation potential (Figure 1I)
and displaying numbers of population doublings and prolifera-
tion rates similar to those observed in primary OFMSCs (Fig-
ure 1J). To confirm that OFMSCs contributed to stromal tissue
growth in the implants, we showed that cells in both 1 and 2
implants were positively stained for anti-human-specific
mitochondrial antibody (Figure 1H). These data imply that
single-colony-derived OFMSCs are capable of self-renewal
and differentiation in vivo.
TGF-b Signaling Is Highly Activated in OFMSCs
We then determined the molecular mechanisms responsible for
the increased self-renewal and decreased osteogenic differenti-
ation of OFMSCs. AlthoughHrpt2mutation and haploinsufficient
expression have been reported in roughly 10% of patients with
OF lesions (Pimenta et al., 2006), the OF tumors from the four
patients recruited in this study did not harbor any Hrpt2 muta-
tions. We compared the global gene profile of OFMSCs and
JMSCs, using microarray and cluster analysis (Figure S2A).
Gene ontology by ingenuity pathway analysis (IPA) demon-
strated that certain genes in the TGF-b and Notch signaling path-
ways were highly differentially expressed, being enriched in
OFMSCs (Figure S2B). Given the fact that TGF-b signaling is
involved in mesenchymal cell proliferation and tumor develop-
ment, we then investigated the role of TGF-b in the signaling
regulation of OFMSCs (Bruna et al., 2007; Ikushima et al.,
2009; Pen˜uelas et al., 2009).
TGF-b1 is secreted into the extracellular matrix in a latent form,
which is subsequently cleaved into an active form to serve its
regulatory function (Pedrozo et al., 1999; Pfeilschifter et al.,
1990). As shown by ELISA, activated TGF-b1 was increased in
the culture supernatant of OFMSCs, as compared to control
JMSCs (Figures 2A and S2D). Western blot analysis confirmed
that activated TGF-b1, but not latent TGF-b1, was upregulated
in OFMSCs (Figures 2B and S2E). At the receptor level, expres-
sion of TGF-b receptors I and II in OFMSCs was slightly
decreased, as compared to control JMSCs (Figure S2C). To
confirm the upregulated TGF-b1 activity in OFMSCs, we evalu-
ated downstream targets of the canonical TGF-b pathway,
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Figure 1. OF Lesions Contain Mesenchymal Stem Cells
(A) OFMSCs generated more single-colony clusters (colony-forming unit fibroblasts, CFU-f) than control JMSCs when cultured at a low density. Culture-
expanded OFMSCs showed an elevated number of BrdU-positive cells as compared to the control JMSCs. Continued culture assay showed that OFMSCs have
a higher rate of population doubling than do JMSCs.
(B) Immunohistochemical staining showed that OF samples contain more PCNA-positive cells than do normal jawbone samples.
(C) Alizarin red staining showed that OFMSCs exhibited decreased capacity to form mineralized nodules under osteogenic inductive culture conditions as
compared to JMSCs. In addition, OFMSCs showed downregulation of the osteogenic markers RUNX2 and OCN, as assessed by western blot analysis.
(D) OFMSCs exhibited decreased capacities to form Oil Red O-positive adipocytes under adipogenic inductive conditions and express the adipogenic markers
PPARg2 and LPL, as shown by western blot analysis.
(E) OFMSCs showed decreased capacity for chondrogenic differentiation, as indicated by the formation of less toluidine-blue-positive chondrocytes when
cultured under chondrogenic conditions and the expression of lower levels of Sox9 and Collagen II, as confirmed by western blot analysis.
(F) Left panel: H&E section of normal human jawbone and OF tissue as indicated. The OF lesion contained a reduced amount of bone (B) and increased stromal
connective tissue (CT) as compared to the control jawbone. Right panel: when implanted into immunocompromised mice with HA/TCP (HA), OFMSCs regen-
erated less bone and more stromal connective tissue than did JMSCs, recapitulating original OF characteristics. Quantitative analysis of bone volume by ImageJ
showed a significant reduction of bone volume in OFMSC implants.
(G) Schema of serial implantation of single-colony-derived MSCs. Single-colony-derived MSCs were expanded to 23 106 cells and subsequently implanted into
immunocompromisedmice with the use of gelfoam as a carrier (1 implant). After 3 weeks, 1 implants were harvested and enzymatically digested for the release
of single cells for in vitro expansion, and 2 3 106 human cells from 1 implants were implanted into immunocompromised mice for the formation of 2 OFMSC
implants.
(H) Single-colony-derivedOFMSCswere capable of forming larger stromal tissuemasses in gelfoam implants and generatingmore single-colony clusters (CFU-f)
than were control JMSCs. Human mitochondria immunohistochemical staining confirmed that cells isolated from 1 and 2 MSC implants were of human origin.
(I) OFMSCs derived from 1 and 2 implants showed the same capacity as parental OFMSCs to form mineralized nodules (as assessed by alizarin red staining)
and adipocytes (as assessed by Oil Red O staining).
(J) BrdU labeling assays showed that OFMSCs derived from 1 and 2 implants possess proliferation capacities similar to those of parent OFSMCs. Continued
culture assays showed that OFMSCs derived from 1 and 2 implants had population doubling rates similar to those of parent OFSMCs.
Data are represented as the mean ± SD of five independent experiments. (*p < 0.05, **p < 0.01). Scale bar represents 100 mm (F) or 50 mm (H). See also Figure S1
and Table S2.
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Benign Tumor Mesenchymal Stem Cells in Ossifying FibromaSMAD2/SMAD3/SMAD4. Interestingly, OFMSCs showed
elevated phosphorylated SMAD3 when compared to JMSCs,
while phosphorylated SMAD3 was not detected in JMSCs (Fig-Cellures 2C and S2F). In addition, expression levels of total
SMAD3 and SMAD4 were consistently higher in OFMSCs than
in JMSCs (Figures 2C and S2F). When induced with TGF-b1, aStem Cell 13, 577–589, November 7, 2013 ª2013 Elsevier Inc. 579
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Figure 2. TGF-b Signaling Is Upregulated in OFMSCs
(A) ELISA analysis showed that the levels of active TGF-b1 were increased in OFMSC culture supernatant as compared to JMSC cultures.
(B and C) Western blots showed that the expression levels of activated TGF-b1, but not latent TGF-b1, were significantly increased in OFMSCs (B). Compared to
control JMSCs, OFMSCs expressed elevated levels of SMAD3, SMAD4, and phosphorylated SMAD3. When treated with 2 ng ml1 TGF-b1, OFMSCs showed
more significant elevation of p-SMAD3, but the expression levels of SMAD3 and SMAD4 showed no significant change (C).
(D) When treated with 2 ng ml1 TGF-b1, the expression levels of the TGF-b/SMAD3 downstream genes Pai-1 and Smad7 were significantly upregulated in
OFMSCs in comparison to the control JMSCs, as determined by real-time PCR.
(E) OFMSCs showed increased SBE4-luciferase activity as compared to JMSCs, and 2 ngml1 TGF-b1 treatment resulted in significantly higher SBE4-luciferase
activity in OFMSCs than in JMSCs.
(F and G) In vitro blockage of TGF-b signaling by 1 mM TbRI inhibitor SB431542 treatment resulted in a marked upregulation of the osteogenic markers RUNX2
and OCN in OFMSCs, along with an elevated capacity to form mineralized nodules in vitro, as assessed by alizarin red staining (F). When implanted into
immunocompromised mice with HA/TCP (HA), SB431542-treated OFMSCs showed a significantly increased capacity to form bone (B) in vivo, as shown by H&E
staining (G).
(H) 1 mM SB431542 treatment also improved osteogenic differentiation of OFMSCs derived from 1 implants, as determined by alizarin red staining, which
showed increased mineralized nodule formation, and western blot analysis, which showed upregulation of the osteogenic markers RUNX2 and OCN.
(I and J) Knockdown of TbrI or Smad3 by siRNA elevated osteogenic differentiation of OFMSCs, as indicated by alizarin red staining, which indicated mineralized
nodule formation, and western blot analysis, which indicated expression of the ostegenic markers RUNX2 and OCN.
Data are represented as the mean ± SD of five independent experiments. (*p < 0.05, **p < 0.01, ***p < 0.001). Scale bar represents 100 mm. See also Figures S2
and S3 and Tables S1 and S2.
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Benign Tumor Mesenchymal Stem Cells in Ossifying Fibromamarked upregulation of phosphorylated SMAD3 and the TGF-b
downstream target genes Pai-1 and Smad7 was observed in
OFMSCs, as compared to TGF-b1-treated JMSCs (Figures 2C
and 2D). Functional analysis showed higher SBE4-luciferase
activity in OFMSCs as compared to JMSCs, both at the basal580 Cell Stem Cell 13, 577–589, November 7, 2013 ª2013 Elsevier Inlevel and in response to TGF-b1 treatment, providing further
evidence for the upregulation of TGF-b signaling in OFMSCs
(Figure 2E). To further confirm the TGF-b signaling activity in
OF lesions, we examined a total of 11 archival OF pathologic
samples with histological diagnosis confirmed by pathologists.c.
Cell Stem Cell
Benign Tumor Mesenchymal Stem Cells in Ossifying FibromaImmunohistochemical staining revealed upregulation of TGF-b
signaling in all these specimens, as shown by a significant in-
crease in phosphorylated SMAD2 as compared to normal
jawbone (Figures S2G and S2G’). The cellular components
also displayed abundant PCNA-positive cells, consistent with
an elevated proliferation rate. Statistical analysis using Spear-
man’s correlation test showed a significant correlation between
phosphorylated SMAD2 activity and the number of PCNA-posi-
tive cells, indicating that elevated TGF-b signaling may
contribute to increased cell proliferation in OF neoplasm (Fig-
ure S2H). The elevated level of phosphorylated SMAD2 was
also confirmed in the in vivo OFMSC implants generated from
OFMSCs derived from all four patients (Figure S2I). Additional
studies of the TGF-b1-mediated noncanonical pathways
showed no significant changes in ERK, p38, and JNK signaling
in OFMSCs as compared to JMSCs (Figure S3A).
To further assess the functional role of TGF-b in OFMSCs, we
blocked TGF-b signaling by using a TGF-b receptor I (TbRI)
inhibitor, SB431542, and observed the suppression of TGF-b1
downstream targets Pai-1 and Smad7 in OFMSCs (Figure S3B).
Interestingly, blockage of TGF-b signaling significantly
enhanced osteogenic differentiation of OFMSCs, as indicated
by improved mineralized nodule formation, upregulation of
RUNX2 and OCN, and elevated in vivo bone formation, as
compared to untreated control OFMSCs (Figures 2F and 2G).
However, SB431542 treatment did not improve the osteogenic
activity of JMSCs either in vitro or in vivo (Figures S3C and
S3D). More convincingly, we demonstrated that inhibition of
TGF-b receptor I rescued bone formation in the in vivo implants
derived from STRO-1+/CD146+ OFMSCs (Figure S3E), but not
those derived from STRO-1/CD146 cells (Figure S3E). The
enhanced osteogenic differentiation by SB431542 treatment
was also observed in OFMSCs from 1 OFMSC implants, sug-
gesting that activation of TGF-b signaling is inherited in the serial
in vivo implantation (Figure 2H). Additionally, we showed that
efficient inhibition of TGF-b signaling by TGF-b receptor I (TbrI)
or Smad3 siRNA (Figures S3F and S3G) led to a significant
rescue of osteogenic deficiency in OFMSCs, as evidenced by
increased mineralized nodule formation and expression of
RUNX2 and OCN (Figures 2I, 2J, and S3H). Moreover, inhibition
of TGF-b signaling by Smad3 siRNA also improved OFMSC-
mediated bone formation when OFMSCs were implanted into
immunocompromised mice with the use of hydroxyapatite/
tricalcium phosphate (HA/TCP) as a carrier (Figure S3I). In addi-
tion to osteogenic rescue, SB431542 treatment suppressed
TGF-b-mediated OFMSC proliferation, possibly regulating stro-
mal cell growth in OF lesions (Figure S3J). Collectively, these
results show that TGF-b signaling is highly activated in OFMSCs
and responsible for their osteogenic deficiency and elevated
rate of proliferation (Figure S3K).
TGF-b Inhibits BMPSignaling to ReduceBone Formation
and Activates Notch Signaling to Enhance Stromal
Tissue Growth
Next, we examined the mechanism whereby activated TGF-b
signaling in OFMSCs results in an OF phenotype, characterized
by osteogenic deficiency and stromal overgrowth. It has been
reported that activated TGF-b is able to inhibit BMP signaling
(Chen et al., 2012), which is one of the major pathways control-
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activated TGF-b signaling blocked the BMP pathway to inhibit
osteogenic differentiation of OFMSCs. Quantitative PCR anal-
ysis showed that levels of BMP2, BMP4, BMP5, BMP6, and
BMP7 were all decreased in OFMSCs (Figure S4A). Given the
fact that loss of BMP4– BMP7, but not BMP2, can be compen-
sated by other BMPs during osteogenic cell differentiation
(Chen et al., 2012), we selected BMP2 as a representative ligand
to study how BMP signaling regulates OFMSCs. OFMSCs
showed downregulated expression of BMP2 as well as BMP
downstream genes Smad6 and Id1 (Figure 3A). In response to
BMP2 treatment, OFMSCs also showed decreased expression
of phosphorylated SMAD1 (Figure 3B). In addition, the expres-
sion levels of Id1 and Smad6 were downregulated in OFMSCs
in the presence of BMP2 (Figure 3C). Blockage of TGF-b
signaling by Smad3 siRNA or SB431542 led to upregulation of
phosphorylated Smad1 and downstream targets Id1 and
Smad6 in OFMSCs (Figures 3D and 3E). These data indicate
that TGF-b signaling downregulates BMP/SMAD1 signaling to
inhibit osteogenic differentiation of OFMSCs.
In addition to their osteogenic deficiency, OFMSCs were
capable of active proliferation, along with formation of abundant
stromal tissue, when implanted in vivo. We then examined
whether activated TGF-b signaling in OFMSCs contributes to
elevated cell proliferation and stromal tissue growth. Notch
signaling is responsible for tissue growth in a variety of tumors
(Ranganathan et al., 2011), and its interaction with TGF-b
signaling has been described in normal basal stem cell activity
in the prostate (Valdez et al., 2012). Using microarray analysis,
we showed that Notch signaling genes were upregulated in
OFMSCs in comparison to JMSCs (Table S1). After confirming
elevated expression of specific Notch signaling genes Jagged1,
Notch3, and Hes1 in OFMSCs and OF samples (Figures 3F and
S4B), we showed that inhibition of TGF-b signaling by TbRI
inhibitor or Smad3 siRNA resulted in downregulation of these
Notch genes (Figures 3G and 3H), suggesting that TGF-b
governs Notch signaling in OFMSCs. To verify that Notch
signaling activation contributes to OFMSC proliferation and
stromal tissue growth, we treated cells with Jagged1 siRNA (Fig-
ure S4C) or Notch inhibitor DAPT and found that inhibition of the
Notch pathway reduced the proliferation rate of OFMSCs (Fig-
ures 3I). As expected, JAGGED1 treatment elevated the OFMSC
proliferation rate (Figure 3I). We further demonstrated that TGF-
b1 treatment enhanced the proliferation of OFMSCs, which was
abrogated by Jagged1 siRNA or DAPT treatment (Figure 3J).
More compellingly, we showed that SB431542 and DAPT treat-
ment suppressed OFMSC-mediated stromal tissue growth of
the in vivo implants in immunocompromised mice (Figure 3K).
Notch signaling has been reported to maintain the undifferenti-
ated state of both MSCs and osteoblasts; therefore, osteogenic
deficiency of OFMSCs may be affected by altered Notch
signaling (Engin and Lee, 2010). However, knockdown of Jag-
ged1 expression by siRNA failed to affect OFMSC-mediated
in vitro calcification, as assessed by alizarin red staining, and
osteogenesis, as assessed by western blot to show the expres-
sion levels of RUNX2 and OCN (Figures S4C and S4D). These
findings suggest that TGF-b promotes OFMSC proliferation
and stromal tissue growth via upregulation of Notch signaling
(Figure S4E).
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Figure 3. TGF-b Inhibits BMP Signaling to Reduce Bone Formation and Activates Notch Signaling to Enhance Stromal Cell Growth
(A) Western blot analysis showed that OFMSCs expressed reduced levels of BMP2 and the BMP downstream genes Id1 and Smad6 in comparison to the control
JMSCs.
(B) When treated with BMP2 at 5-50 ng ml1, OFMSCs showed reduced expression of phosphorylated SMAD1 in comparison to the control JMSCs.
(C) Real-time PCR analysis revealed that the expression levels of the BMP downstream genes Id1 and Smad6 decreased in OFMSCs in the presence of 5 ngml1
BMP2, as compared to the control JMSCs.
(D) Western blot analysis showed that knockdown of TGF-b signaling by Smad3 siRNA resulted in upregulation of p-SMAD1 in OFMSCs.
(E) TbRI inhibitor SB431542 treatment also upregulated the BMP downstream genes Id1 and Smad6, as assessed by real-time PCR.
(F) Western blot analysis revealed that OFMSCs had upregulated expression of the Notch signaling genes Jagged1,Notch3, and Hes1 in comparison to JMSCs.
(G and H) Western blot analysis showed that inhibition of TGF-b signaling by 1 mM of the TbRI inhibitor SB431542 or Smad3 siRNA treatment resulted in
downregulation of the Notch signaling genes Jagged1, Notch3, and Hes1.
(I) Activating Notch signaling by 100 ng ml1 JAGGED1 treatment could elevate OFMSC proliferation. However, blockage of the Notch pathway by Jagged1
siRNA or treatment with 1 mM of the Notch signaling inhibitor DAPT reduced the OFMSC proliferation rate, as shown by BrdU labeling assays.
(J) BrdU labeling assays indicated that TGF-b increased the proliferation rate of OFMSCs, whereas DAPT or Jagged1 siRNA abrogated the effect.
(K) Blockage of TGF-b signaling by SB43154 treatment or of the Notch pathway by DAPT treatment resulted in a significantly reduced growth of stromal tissue in
implanted OFMSCs. The OF-like tissue volume was calculated by the following formula: volume = length 3 width2 3 0.52.
Data are represented as the mean ± SD of five independent experiments. (*p < 0.05, **p < 0.01). See also Figure S4 and Table S2.ET
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Benign Tumor Mesenchymal Stem Cells in Ossifying FibromaUpregulation of TSP1Contributes to Activation of TGF-b
Signaling in OFMSCs
Our data showed that although there appeared to be no signif-
icant increase in expression of TGF-b receptors or latent TGF-b
in OFMSCs from our four studied patients as compared to
JMSCs, activated TGF-b1 signaling and mediated target gene
expression were significantly enriched in OFMSCs (Figures
2A, 2B, and S2C). Therefore, we hypothesized that activation
of TGF-b signaling in OFMSCs may originate upstream of
TbRI, perhaps with increased activation of TGF-b ligand.
TSP1 is known to facilitate the conversion of latent TGF-b to
active TGF-b (Murphy-Ullrich and Poczatek, 2000), and our
microarray data identified elevated expression of Tsp1 in
OFMSCs (Table S1). We confirmed that TSP1 was highly ex-
pressed in OFMSCs and OF tissues by western blot, real-time
PCR, and immunohistochemical staining (Figures 4A–4C).
Upon exposure to TSP1, OFMSCs displayed significant upre-
R582 Cell Stem Cell 13, 577–589, November 7, 2013 ª2013 Elsevier Ingulation of activated TGF-b, as assessed by western blot and
ELISA analysis (Figures 4D and 4E). These results suggest
that TSP1 contributes to the activation of TGF-b signaling in
OFMSCs.
Next, we examined whether elevated TSP1 affected osteo-
genic activity in OFMSCs. As shown by alizarin red staining,
Tsp1 knockdown by siRNA or TSP1 block peptide treatment
in OFMSCs effectively increased mineralized nodule formation
in vitro, whereas control peptide treatment showed no effect
(Figure 4F). Moreover, elevated RUNX2 and OCN expression
was induced in Tsp1 siRNA and block-peptide-treated
OFMSCs (Figures 4F and 4G). These results indicate that
elevated TSP1 in OFMSCs promoted TGF-b signaling to nega-
tively regulate osteogenic differentiation. Consistent with the
role of TGF-b signaling in stromal growth, Tsp1 knockdown
by siRNA also decreased the OFMSC proliferation rate
(Figure 4H).c.
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Figure 4. Upregulation of TGF-b in OFMSCs Results from Elevated TSP1 Expression
(A and B) Western blot analysis and real-time PCR showed that OFMSCs had elevated expression of TSP1 as compared to the control JMSCs.
(C) Immunohistochemical staining showed that OF samples contained more TSP1-positive cells than did normal jawbone.
(D and E) TSP1 treatment increased expression levels of activated TGF-b1 in OFMSCs, as assessed by western blot (D) and ELISA analysis (E).
(F) Knockdown of Tsp1 expression by Tsp1 siRNA or 5 mM TSP1 block peptide LSKL treatment improved osteogenic differentiation of OFMSCs, as indicated by
elevated mineralized nodule formation assessed by alizarin red staining, and upregulation of the osteogenic markers RUNX2 and OCN, as assessed by western
blot analysis. 5 mM SLLK was used as a control peptide.
(G) Efficacy of Tsp1 siRAN was assessed by western blot. (H) Knockdown of Tsp1 by siRNA can inhibit the proliferation of OFMSCs.
Data are represented as the mean ± SD of five independent experiments. (*p < 0.05, **p < 0.01). Scale bar represents 100 mm (F) or 50 mm (C).
R
A
C
TE
D
Cell Stem Cell
Benign Tumor Mesenchymal Stem Cells in Ossifying FibromaHistone Demethylase JHDM1D-Mediated TSP1/TGF-b/
SMAD3 Autocrine Loop Contributes to TGF-b Activation
To further investigate the mechanism underlying TGF-b-driven
benign tumor growth in OF, we examined the regulatory circuit
of Tsp1. We found that TGF-b1 treatment upregulated Tsp1
expression in OFMSCs in a time-dependent manner, a property
not detected in JMSCs (Figure 5A). As confirmed by western
blot, TGF-b1 treatment increased TSP1 expression in OFMSCs,
but not in JMSCs (Figure 5B). Inhibition of TGF-b signaling by the
TbRI inhibitor SB431542, TbrI siRNA, or Smad3 siRNA signifi-
cantly reduced TSP1 expression in OFMSCs (Figures 5B and
5C). These data indicate that inhibition of TGF-b/SMAD3
signaling reduced the level of TSP1.
Different downstream gene expression in response to TGF-b
may result from promoter methylation status, as indicated by
Pdgf-b expression in gliomas (Bruna et al., 2007). The methyl-
ation status of the Tsp1 promoter, however, showed no differ-
ence between OFMSCs and JMSCs (Figure S5A), indicating
that other epigenetic mechanisms may regulate the expression
of Tsp1. Histone methylation and demethylation are antagonistic
mechanisms employed by cells tomodulate gene expression. Of
the genes with different expression levels in OFMSCs and
JMSCs, we identified JHDM1D, a histone demethylase, to be
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by western blot and immunhistochemical staining (Figures 5D
and S5B). JHDM1D, also known as KIAA1718, is part of a histone
demethylation subfamily along with PHF2 and PHF8. JHDM1D
performs a versatile array of histone modification and plays a
pivotal role in regulating craniofacial development (Qi et al.,
2010). Among the JHDM1D-mediated histone modifications,
we found a marked suppression of the repressive histone
modification marks H3K9me1, H3K9me2, H3K27me2, and
H4K20me1 in OFMSCs in comparison to JMSCs (Figure 5D).
Knockdown of Jhdm1d by siRNA in OFMSCs induced downre-
gulation of TSP1 and Tsp1-luciferase activity, as well as active
TGF-b, suggesting that Tsp1 expression and active TGF-b levels
may be regulated by JHDM1D activity (Figures 5E, 5F, and S5C).
Moreover, JHDM1D knockdown by siRNA significantly
increased methylation levels of H3K9, H3K27, and H4K20 in
the promoter of the Tsp1 gene, indicating that JHDM1D may
be essential for regulation of methylation status (Figure S5D).
To further investigate the role of JHDM1D in TGF-b-mediated
gene expression, we found Jhdm1d siRNA could rescue TGF-
b1-mediated downregulation of H3K9me2 in OFMSCs (Fig-
ure 5G). We showed that increased levels of H3K9me1 and
H4K20me1, induced by TGF-b1 treatment, were also reducedStem Cell 13, 577–589, November 7, 2013 ª2013 Elsevier Inc. 583
A B C
D E F G
H
K
I J
L
Figure 5. Histone Demethylase JHDM1D-Mediated JHDM1D/TSP1/TGF-b/SMAD3 Autocrine Loop Contributes to TGF-b Activation
(A) When treated with 2 ng ml1 TGF-b1 for 0, 3, 6, and 12 hr, OFMSCs showed a significantly increased production of Tsp1 in comparison to control JMSCs, as
shown by real-time PCR.
(B) Western blot analysis showed that TGF-b1 treatment elevated the TSP1 expression level in OFMSCs, but not in JMSCs. Upregulation of TSP1 in OFMSCswas
reduced by 1 mM of the TbRI inhibitor SB431542 or TbrI siRNA treatment.
(C) Western blot analysis showed that Smad3 siRNA treatment significantly reduced TGF-b1-induced TSP1 expression.
(D) Western blot analysis showed that OFMSCs expressed elevated levels of JHDM1D and reduced H3K9me1, H3K9me2, H3K27me2, and H4K20me1.
(E and F) Knockdown of Jhdm1d by siRNA induced downregulation of TSP1 and activated TGF-b1 in OFMSCs, as determined by western blot analysis (E) and
Tsp1-luciferase activity (F).
(G) Western blot analysis showed that 2 ng ml1 TGF-b1 treatment upregulated H3K9me1 and H4K20me1 and downregulated H3K9me2 and had no effect on
H3K27me2 in OFMSCs. However, TGF-b1 treatment upregulated H3K9me2, H3K27me2, and H4K20me1 and had no effect on H3K9me1 in JMSCs. Knockdown
of Jhdm1d by siRNA significantly increased H3K9me2 levels and decreased the H3K9me1 and H4K20me1 levels in TGF-b1-treated OFMSCs. Knockdown of
Jhdm1d appeared to have no significant effect on H3K9me2 or H4K20me1 levels in TGF-b1-treated JMSCs.
(H–J) ChIP-PCR analysis indicated that JHDM1D bound to the Tsp1 promoter in the presence of 2 ng ml1 TGF-b1 in OFMSCs (H), but not in JMSCs (I). Smad3
siRNA treatment resulted in significantly reduced binding of JHDM1D to the Tsp1 promoter (J).
(K) ChIP-PCR analysis indicated a lower level of the repressive histone modification marks H3K9me1, H3K9me2, H3K27me2, and H4K20me1 in the Tsp1
promoter in OFMSCs as compared to JMSCs.
(L) ChIP-PCR analysis showed that the levels of H3K9me1, H3K9me2, H3K27me2, and H4K20me1 in the Tsp1 promoter were increased inOFMSCswhen treated
with 1 mM TbRI inhibitor SB431542.
Data are represented as the mean ± SD of five independent experiments. (*p < 0.05, **p < 0.01, ***p < 0.001; #, not significant). See also Figure S5 and Table S2.
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although TGF-b1 treatment affected the level of some histone
modification marks, knockdown of Jhdm1d failed to alter their
levels. These data indicate that JHDM1D specifically regulates
histone modification in OFMSCs. To determine how JHDM1D
regulates Tsp1 expression in OFMSCs, we examined the
JHDM1D binding site at the Tsp1 promoter through a ChIP-
PCR assay. Among the different tested regions around the tran-
scriptional start site (TSS) of the Tsp1 gene, JHDM1D binds at
the region 1kb from the TSS when treated with TGF-b1 (Fig-
ure 5H), whereas no JHDM1D binding was detected in JMSCs
(Figure 5I). TGF-b1-mediated JHDM1D binding to the Tsp1
promoter was abrogated by Smad3 knockdown, suggesting
that SMAD3 signaling mediates the binding (Figure 5J). Consis-
tent with the Tsp1 expression, OFMSCs showed reduced
repressive histone marks H3K9me1, H3K9me2, H3K27me2,
and H4K20me1 at the Tsp1 promoter in comparison to JMSCs
(Figure 5K). Inhibition of TGF-b signaling by the TbRI inhibitor
SB431542 increased these repressive histone marks at the
Tsp1 promoter (Figure 5L), consistent with the decreased
expression of TSP1 after treatment with the TbRI inhibitor
SB431542 (Figure 5B). Given the fact that JHDM1D expression
is highly elevated in OFMSCs as compared to JMSCs, SMAD3
may enhance JHDM1D transcription by binding to the JHDM1D
promoter. We further showed that SMAD3 can bind to the
JHDM1D promoter region, suggestive of transcriptional regu-
lation of JHDM1D by SMAD3 (Figure S5E). These findings
collectively suggest that activated TGF-b/SMAD3 signaling
upregulates Tsp1 expression by histone modification and that
TSP1 can regulate the conversion of the latent form of TGF-b
to the active form, thus establishing a positive JHDM1D/TSP1/
TGF-b/SMAD3 feedback loop in OFMSCs (Figure S5F).
Establishment of TSP1/TGF-b/SMAD3 Autocrine Loop
Converts Normal MSCs to OF-like MSCs
Given that a previous study suggested that chronic TGF-b treat-
ment can establish epigenetic regulation of cell function (Bechtel
et al., 2010), we tested whether long-term activation of TGF-b
signaling in JMSCs could establish the JHDM1D/TSP1/TGF-b/
SMAD3 autocrine loop. Indeed, JMSCs treated with TGF-b1
for 5 days showed an elevated proliferation rate and reduced
osteogenesis, as observed in OFMSCs (Figures 6A and S6A).
Sirius red and trichrome staining further confirmed that TGF-
b1-treated JMSCs exhibited an in vivo differentiation pattern
similar to that observed in OFMSCs, characterized by increased
stromal tissue formation (Figure 6B). When implanted into immu-
nocompromised mice with the use of gelfoam as a carrier, TGF-
b1-treated JMSCs acquired aberrant stromal tissue growth
in vivo, as observed in gelfoam OFMSC implants (Figure 6C).
These results indicate that TGF-b1 can increase the in vivo
self-renewal capacity of JMSCs, a feature lacking in normal
JMSCs.
To examine whether long-term TGF-b1 treatment induces
JMSCs to display molecular characteristics of OFMSCs, we
showed that TGF-b1 treatment induced the upregulation of
JHDM1D and TSP1 in JMSCs (Figures 6D and S6B). Moreover,
TGF-b1-treated JMSCs showed downregulation of the BMP
signaling genes Id1 and Smad6, as well as upregulation of the
Notch pathway genes Jagged1, Notch3, and Hes1 (Figures
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JMSCs showed enrichment of JHDM1D at the Tsp1 promoter
(Figure 6E). Smad3 knockdown by siRNA during the process of
TGF-b1 treatment abrogated JHDM1D binding (Figure S6E).
Accordingly, TGF-b1-treated JMSCs showed reductions in
the histone marks H3K9me1, H3K9me2, H3K27me2, and
H4K20me1 (Figure 6F) at the Tsp1 promoter. These data suggest
that the establishment of epigenetic regulation of JHDM1D/
TSP1/TGF-b/SMAD3 is an inducible mechanism following
TGF-b1 treatment in JMSCs with characteristics similar to those
of OFMSCs.
DISCUSSION
Because of their relatively ‘‘benign’’ nature, benign tumors are
frequently managed with surgical excision as a therapeutic
approach, but postsurgical recovery and malignant transforma-
tion remain challenges (Colmenero-Ruiz et al., 2011; Zama et al.,
2004). A major question that could transform this therapeutic
approach is whether cells derived from benign tumors can be
induced to return to a normal state. Multiple lines of evidence
have suggested that cancer stem cells in different types of
malignant tumors are responsible for sustaining tumorigenesis
and functional heterogeneity (Visvader and Lindeman, 2012);
however, it remains unclear whether a similar population of
stem-like cells exists in benign neoplasm or dysplasia and, if
so, how their molecular characteristics differ from those of
normal counterparts. In this study, we found that OF, a benign
neoplasm, contains a unique population of mesenchymal stem
cells (OFMSCs) that can recapitulate the parental tumor pheno-
type when implanted in vivo and identified TGF-b signaling as a
key regulator for their benign tumor stem-like cell phenotype.
Furthermore, we showed that inhibition of TGF-b signaling can
induce OFMSCs to convert to being ‘‘normal’’ MSCs with
enhanced osteogenic activity and a reduced proliferation rate,
suggesting a potential therapeutic avenue for guiding benign tu-
mor stem cells to function normally.
OFMSCs are capable of forming single-colony clusters, ex-
pressing specific stem cell surfacemarkers, responding to differ-
entiating induction cues, and generating tumors when implanted
in vivo, thus meeting the primary criteria for classification as
cancer stem cells. More importantly, transplantation of OFMSCs
can recapitulate parental tumor phenotypes with increased self-
renewal and osteogenic deficiency, thus serving as a platform for
developing therapeutic approaches. Although OFMSCs share
some similarities with their normal counterparts (JMSCs), the
difference is quite prominent. High efficiency in a CFU-f assay
implied that OFMSCs, but not JMSCs, were capable of
increasing self-renewal, which was further confirmed in both 1
and 2 implantation of single-colony-derived OFMSCs. Further-
more, OFMSCs demonstrated significant deficiency in osteo-
genic differentiation. Enhanced self-renewal and decreased
differentiation of OFMSCs may contribute to the OF phenotype:
abnormal stromal cell growth and osteogenic deficiency.
Understanding the difference in molecular regulation between
normal and tumor stem cells is fundamental for the development
of targeted therapies to eradicate tumor cells while minimizing
damage to normal cells. By comparing global gene expression
patterns, we identified TGF-b signaling as a crucial regulator
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Figure 6. Establishment of the JHDM1D/TSP1/TGF-b/SMAD3 Autocrine Loop Converts Normal MSCs to OF-like MSCs
(A) Alizarin red staining showed that long-term TGF-b1 treatment reduced the capacity of JMSCs to formmineralized nodules in vitro and bone formation in vivo in
HA/TCP implants. Decreased osteogenic differentiation was confirmed by western blot analysis showing downregulation of RUNX2 and OCN.
(B) Trichrome and Sirius red staining indicated that long-term TGF-b1 treatment induced fibro-osseous tissue growth in JMSC implants, similar to OFMSC
implants.
(C) When implanted into immunocompromised mice with the use of gelfoam as a carrier, long-term TGF-b1-treated stromal tissue showed elevated formation,
producing tumor-like soft tissue. The tumor volume was calculated by the following formula: volume = length 3 width2 3 0.52.
(D) Western blot analysis showed that long-term TGF-b1 treatment induced the upregulation of TSP1 and JHDM1D in JMSCs.
(E) ChIP-PCR analysis showed JHDM1D binding to the Tsp1 promoter in long-term TGF-b1-treated JMSCs.
(F) ChIP-PCR analysis indicated lower levels of the repressive histone modification marks H3K9me1, H3K9me2, H3K27me2, and H4K20me1 in the Tsp1 pro-
moter in long-term TGF-b1-treated JMSCs as compared to nontreated JMSCs.
Data are represented as the mean ± SD of five independent experiments. (*p < 0.05, **p < 0.01, ***p < 0.001). Scale bar represents 100 mm (A, B) or 50 mm (C). See
also Figure S6.
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of OFMSCs. TGF-b1 generally enhances proliferation of mesen-
chymal cells, but it elicited a particularly strong response in
OFMSCs, including SMAD phosphorylation and downstream
gene expression. More intriguingly, active TGF-b1 is specifically
enriched in OFMSCs in comparison to JMSCs, implicating a role
for TGF-b signaling in OFMSCs and providing a rationale for
investigation into potential therapies based on blocking TGF-b
signaling. As expected, knockdown of TGF-b signaling signifi-
cantly enhanced osteogenesis of OFMSCs, as indicated by
elevated osteogenic gene expression and in vivo bone for-
mation. Elevated expression of other components of TGF-b
signaling, such as SMAD3 and SMAD4, may also contribute to
the activation of TGF-b signaling, but the effectiveness of TbRI
inhibitor SB431542 treatment in OFMSC osteogenesis implies
that enrichment of the active TGF-b ligand may be still a domi-
nant factor in the strong activation of the pathway. Furthermore,
R586 Cell Stem Cell 13, 577–589, November 7, 2013 ª2013 Elsevier Inin spite of enriched active TGF-b, the latent TGF-b1 levels in
JMSCs and OFMSCs are similar.
In a vast array of malignant tumors, TGF-b signaling activity is
adversely associated with prognosis via promoting proliferation,
angiogenesis, metastasis, and suppression of the immune
response (Massague´, 2008; Padua et al., 2008), but the role of
TGF-b signaling in benign tumor behavior is not well character-
ized. One effective strategy for targeting tumor-initiating cells is
to induce them to undergo differentiation and apoptosis, which
is exemplified by the application of retinoic acid in acute promye-
locytic leukemia (Wang and Chen, 2008). Distinct frommalignant
cells, which hardly give rise to any functionally normal differ-
entiated cells, cells in benign tumors, without accumulated
mutations or malignant transformation, have the potential to
differentiate normally. By the same token, OFMSCs can be
induced to function as normal MSCs by downregulating their
TGF-b signaling. Therefore, molecular manipulation of OFMSCsc.
Cell Stem Cell
Benign Tumor Mesenchymal Stem Cells in Ossifying Fibromaprovides promising therapies for OF. Although inhibition of TGF-
b signaling dramatically improves osteogenesis of OFMSCs
in vitro and in vivo, providing a paradigm for OF therapy, ques-
tions regarding how to implement blockage of TGF-b signaling
as a therapy for OF lesions, such as how to induce the functional
pattern in jawbones, still remain in need of further investigation.
The involvement of TGF-b in different tumor types is widely
investigated, but the origin of active TGF-b is rarely uncovered.
In the present study, we have revealed a JHDM1D/TSP1-medi-
ated epigenetic loop responsible for the enrichment of active
TGF-b1 and subsequent elevation of TGF-b signaling. TSP1,
an extracellular matrix glycoprotein, inhibits tumor cell growth
and metastasis by angiogenesis suppression (Boukamp et al.,
1997; Volpert et al., 1998). Malignant tumors also hijacked
TSP1-activated TGF-b for efficient growth to bypass the TSP1-
mediated suppression (Filleur et al., 2001). In OF, TSP1-acti-
vated TGF-b promotes fibro-osseous stromal cell growth and
induces osteogenic deficiency. Intriguingly, Tsp1 expression in
OF is under the regulation of TGF-b signaling, forming a positive
feedback loop that strengthens the activity of TGF-b signaling,
which is distinctive from normal JMSCs.
We determined that TGF-b-driven Tsp1 expression is regu-
lated by the JHDM1D-associated histone modification in
OFMSCs. Upon activation of TGF-b signaling, JHDM1D facili-
tates Tsp1 expression by removing inhibitory histone modifica-
tion. Expression of PHF8, a JHDM1D homolog, is detectable in
the jaw of zebrafish embryos at 3 days postfertilization (dpf),
and injection of PHF8morpholino results in pronounced orofacial
defects, such as absence of the lower jaw (Qi et al., 2010). This
evidence suggests a conserved role of this histone demethylase
family in the normal and pathogenic osteogenesis of orofacial
bones. Given that expression levels of both JHDM1D and
SMAD3 are significantly elevated in OFMSCs as compared to
JMSCs, SMAD3may enhance JHDM1D transcription by binding
to the JHDM1D promoter. Although our data suggest that
SMAD3 may enhance JHDM1D transcription by directly binding
to the JHDM1D promoter region, we cannot exclude the possi-
bility that SMAD3 directly interacts with JHDM1D protein to
regulate its activity. How exactly SMAD3 regulates JHDM1D
activity remains elusive.
The JHDM1D/TSP1-mediated epigenetic loop strengthens
signaling activity and contributes to the cell proliferation and
osteogenic deficiency of OFMSCs. More interestingly, establish-
ment of the epigenetic loop conferred normal JMSCs with OF-
like properties, including decreased osteogenic capacity,
enhanced proliferation, OF-like histone modification, and
increased Tsp1 expression. Prolonged TGF-b treatment could
establish a JHDM1D-mediated TSP1/TGF-b/SMAD3 autocrine
loop, resulting in positive feedback and changing JMSCs into
OF tumor stem-like cells. However, defining the component in
the loop that functions as an initial inducer remains to be
explored. It has been recognized that cells can respond to tran-
sient epigenetic modification to stabilize newly acquired pheno-
typic behavior (Ikegaki et al., 2013); therefore, it is conceivable
that the upregulation of JHDM1Dmight be a key factor in eliciting
activation of the Tsp1 and TGF-b signaling cascade.
In conclusion, our work establishes a human stem-cell-based
benignOF tumormodel with a functional phenotype regulated by
JHDM1D/TSP1/TGF-b/SMAD3 autocrine-mediated hyperactive
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components in OFMSCs can rescue osteogenic deficiency and
suppress stromal growth, therefore providing a unique therapy
for OF lesions.
EXPERIMENTAL PROCEDURES
Primary Cell Cultures
Human OF tissues from surgical resection were obtained upon written
informed consent from patients and IRB approval from the University of South-
ern California (HS-07-00701). Aseptically minced tumor samples were
digested with 200 U/ml collagenase I (Sigma) and 1mg ml1 dispase (Sigma)
in PBS for 2 hr in a 37Cwater bath with intermittent agitation. The cell suspen-
sion was filtered through a 70 mm cell strainer (BD Falcon) for the removal of
undigested tissue mass, centrifuged, and resuspended in complete MSC
culture medium (a-MEM containing 15% fetal bovine serum (FBS), 100 mM
L-ascorbic acid, 100 U/ml penicillin, 100 mg ml1 streptomycin, and 2 mM
L-glutamine). The cells were cultured on a nontreated plastic dish (BD Falcon)
and rinsed twicewith PBS for the removal of nonadherent cells. Confluent cells
were passaged with treatment of 0.05% trypsin and 1 mM EDTA (Invitrogen).
Normal jawbone MSC (JMSC) culture was established from the bone marrow
of human jawbone, according to a previously reported MSC isolation protocol
(Yamaza et al., 2011). In brief, 2 3 106 whole bone marrow cells were centri-
fuged and resuspended in MSC culture medium. The cells were cultured on
a nontreated plastic dish (BD Falcon) and rinsed twicewith PBS for the removal
of nonadherent cells. For long-term TGF-b1 treatment, the cells were treated
with TGF-b1 for 5 days and then cultured in completeMSCmedium.We estab-
lished primary OFMSC culture from four surgically resected OF samples, one
from each of four patients (#1–#4), which were radiographically and histolog-
ically diagnosed as OF lesions with no reactive normal bone around the le-
sions. JMSCs were derived from a pool of normal JMSC samples (n = 4) and
served as the control group.
Subcutaneous Implantation of MSCs
For each subcutaneous implantation, 2 3 106 culture-expanded cells were
mixed with 40 mg HA/TCP (Berkeley Advanced Biomaterials) or gelfoam in
0.5 ml medium and incubated at 37C for 90 min. After a brief centrifuge for
the removal of supernatant, cells and carrier were subcutaneously implanted
into the dorsal surface of female immunocompromised mice. For implants
with long-term TGF-b1 treatment, the cells were treated with TGF-b1 for
5 days prior to implantation. Samples were harvested 8 weeks after implanta-
tion for further analysis. The percentage of bone volume out of the total volume
of each implant was analyzed by NIH Image J as described previously (Liu
et al., 2011; Shi et al., 2002). In brief, five representative fields of hematoxylin
and eosin (H&E) staining were selected, and newly generated mineralized tis-
sue area in each field was calculated as a percentage of the total tissue area.
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